395 related articles for article (PubMed ID: 35934868)
1. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
[TBL] [Abstract][Full Text] [Related]
2. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
3. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease.
Zhu C; Huang D; Ma H; Qian C; You H; Bu L; Qu S
Front Endocrinol (Lausanne); 2022; 13():848937. PubMed ID: 35620390
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
5. Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.
Petralli G; Salvati A; Tricò D; Ricco G; Colombatto P; Brunetto MR; Solini A
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3736. PubMed ID: 37839068
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.
Eren F; Kaya E; Yilmaz Y
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):98-103. PubMed ID: 32976186
[TBL] [Abstract][Full Text] [Related]
8. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
[TBL] [Abstract][Full Text] [Related]
10. Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease.
Lee CH; Lui DT; Li RH; Yuen MM; Fong CH; Leung AP; Chu JC; Mak LL; Lam TH; Woo J; Woo YC; Xu A; Tse HF; Tan KC; Cheung BM; Yuen MF; Lam KS
Front Endocrinol (Lausanne); 2022; 13():1056562. PubMed ID: 36686469
[TBL] [Abstract][Full Text] [Related]
11. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis.
Rodríguez-Antonio I; López-Sánchez GN; Reyes-Gómez VA; Contreras-Flores EH; Farías-García F; Espejel-Deloiza M; Durán-Padilla MA; Chablé-Montero F; Uribe M; Chávez-Tapia NC; Montalvo-Javé EE; Nuño-Lámbarri N
Ann Hepatol; 2022; 27(2):100651. PubMed ID: 34896638
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
[TBL] [Abstract][Full Text] [Related]
16. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.
Ding Y; Deng Q; Yang M; Niu H; Wang Z; Xia S
Diabetes Metab Syndr Obes; 2023; 16():3303-3329. PubMed ID: 37905232
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
18. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
[TBL] [Abstract][Full Text] [Related]
19. Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease.
Huh JH; Kim KJ; Kim SU; Cha BS; Lee BW
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):241-247. PubMed ID: 35365418
[TBL] [Abstract][Full Text] [Related]
20. Influence of type 2 diabetes mellitus on liver histology among morbidly obese individuals. A cross-sectional study.
Cazzo E; Jimenez LS; Gallo Fde F; Pareja JC; Chaim EA
Sao Paulo Med J; 2016; 134(1):79-83. PubMed ID: 26786607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
